Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model.
JIT, M; Brisson, M; Laprise, J-F; Choi, YH;
2015
BMJ (Clinical research ed), (2015).350 jan06 10.1136/bmj.g7584.
Continuing effectiveness of serogroup A meningococcal conjugate vaccine, Chad, 2013.
Gamougam, K; Daugla, DM; Toralta, J; Ngadoua, C; Fermon, F; Page, A-L; Djingarey, MH; Caugant, DA; MANIGART, O; Trotter, CL; Stuart, JM; GREENWOOD, BM;
2015
Emerging infectious diseases, (2015).21 1 10.3201/eid2101.140256.
Duration of protection of infant BCG vaccination in Ethnic minority groups in England.
MANGTANI, P; NGUIPDOP-DJOMO, P; KEOGH, R; Abubakar, I; SMITH, PG; RODRIGUES, LC;
2015
46th Union World Conference on Lung Health (2015).
ProVac Global Initiative: a vision shaped by ten years of supporting evidence-based policy decisions.
Jauregui, B; Janusz, CB; CLARK, AD; Sinha, A; Garcia, AG F; Resch, S; Toscano, CM; SANDERSON, C; Andrus, JK;
2014
Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.080.
Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
Kieninger, MP; Caballero, EG; Sosa, AA; Amarilla, CT; Jáuregui, B; Janusz, CB; CLARK, AD; Castellanos, RM;
2014
Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.078.
Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei, C; Odaga, J; Mvundura, M; Madrid, Y; CLARK, AD; Kenya ProVac Technical Working Group,; Uganda ProVac Technical Working Group,;
2014
Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.079.
Factors associated with tuberculosis infection, and with anti-mycobacterial immune responses, among five year olds BCG-immunised at birth in Entebbe, Uganda.
Lule, SA; MAWA, PA; NKURUNUNGI, G; Nampijja, M; Kizito, D; Akello, F; Muhangi, L; ELLIOTT, AM; WEBB, EL;
2014
Vaccine, (2014).33 6 10.1016/j.vaccine.2014.12.015.
Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti, A; Preza, I; Simaku, A; Nelaj, E; CLARK, AD; Felix Garcia, AG; Lara, C; Hoestlandt, C; Blau, J; Bino, S;
2014
Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.075.
Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.
Mezones-Holguin, E; Canelo-Aybar, C; CLARK, AD; Janusz, CB; Jaúregui, B; Escobedo-Palza, S; Hernandez, AV; Vega-Porras, D; González, M; Fiestas, F; Toledo, W; Michel, F; Suárez, VJ;
2014
Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.039.
Cost-effectiveness of HPV vaccination in Belize.
Walwyn, L; Janusz, CB; CLARK, AD; Prieto, E; Waight, E; Largaespada, N;
2014
Vaccine, (2014).33 Sup S1 10.1016/j.vaccine.2014.12.042.